# Tianjin Suntech Pharmaceutical Technology Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/tianjin-suntech-pharmaceutical-technology-co

- Industry: Pharmaceuticals
- Headquarters: Tianjin, China
- Website: www.accendatech.com
- Latest round: Series C (May 1, 2022)
- Investors on record: 3

## About

Established in 2008 and based in Tianjin, China, Tianjin Suntech Pharmaceutical Technology Co., Ltd. has research and development centers in Australia and China. The company mainly engages in the development of new drugs for anti-cancer stem cells and autoimmune diseases and has obtained 9 phase 1-2 clinical trial approvals in China, the United States and Australia, etc. The company's product ACT001 has been granted orphan drug status in the United States and the European Union, and is one of the top 10 products independently developed in China to obtain orphan drug status in the United States. The company was ranked No. 100 in the 2020 China Chemical Research and Development Strength Ranking, the founders of the company Prof. Peng Wang is a Changjiang Scholar and Claude S. Hudson Award recipient, and Yue Chen is a National Outstanding Youth Fund recipient.

The company develops products with special focus on active ingredients in Chinese medicine, using modern medicinal chemistry strategies for structural optimization, resulting in drug candidates with new structures and mechanisms, which should mainly fight against cancer stem cells and autoimmune diseases, with a focus on new drugs that enter the cranium. The company currently has two unique technology platforms, namely "Open/Modulated Blood-Brain Barrier Platform" and "Cancer Stem Cell Targeted Drug Development Platform". The company is currently known to manufacture ACT001, mainly for children with DIPG; meanwhile, the results of the company's clinical phase 1b/2a trial of combined radiotherapy for the treatment of brain metastases from cancer have been included in ASCO (Abstract#366152). In the past few years, the company has completed ACT001 Phase IIa trials in China and Australia for the treatment of DIPG, FDA clinical phase II green pass in the U.S., phase II in Australia for pulmonary fibrosis, and phase II in China for brain metastases from cancer.

The company raised a series C funding in May 2022, this round of funding is mainly used for ACT001, ACT004 and other pipeline clinical project trial promotion, talent introduction, marketing preparation and other related work.

## Funding rounds

- Series C, May 1, 2022 — Shenzhen Guozhong Venture Capital, Yunsong Capital, Hengjian Holding

## Investors

- Shenzhen Guozhong Venture Capital (https://capitalatlas.ai/funds/shenzhen-guozhong-venture-capital) — Series C
- Yunsong Capital (https://capitalatlas.ai/funds/yunsong-capital) — Series C
- Hengjian Holding (https://capitalatlas.ai/funds/hengjian-holding) — Series C